MNPHARM molecular farming combines technology advances in plant microbial genetic engineering, protein purification and controlled indoor agriculture to supply the therapeutic development community rapid access to affordable recombinant protein.
Compared to other means of protein production, molecular farming offers the lowest overall cost for production, a very high scale-up capacity and short production times with exceptional product quality. Plants assemble difficult to-make and multi-subunit proteins with proper post-translational modifications for humans. Engineered plants produce glycosylated proteins identical to that obtained from mammalian cell culture, with a low contamination risk from endotoxins, viruses, prions and oncogenic DNA.
MNPHARM, SBC., has exclusive rights to a transient expression platform tailored for high yields of pure protein using transgenic plants. Since researchers are currently paying up to $7,500 per milligram for recombinant regenerative proteins, our most immediate goal is to build infrastructure and expertise that reduces the cost of recombinant proteins by 100-fold.
Detailed techno-economic analyses predict future protein production costs of less than $1.00 per milligram at a production scale of 300 kilogram of protein per year. In summary, the major advantages for molecular farming include scalability, speed, yield, quality, safety and cost.
By lowering the cost of proteins needed for therapeutic development, MNPHARM achieves its stated goal of “Advancing Plant Based Medicine” by increasing the pace of therapeutic discovery allowing remedy’s for disease to become available to the public much quicker.